(TIVC) Tivic Health Systems, Inc. Company Overview

Tivic Health Systems, Inc. completed a corporate name and ticker change on April 28, 2026, becoming Valion Bio, Inc. (Nasdaq: VBIO). The legacy TIVC identity therefore describes the same public company before its rebranding, not a separate operating business. The change followed a much deeper transformation: Tivic exited its consumer bioelectronic-device operations and rebuilt itself as a clinical-stage biopharmaceutical company centered on innate-immune modulation. The official name-change filing confirms that TIVC ceased trading and VBIO began trading on the Nasdaq Capital Market.

What is the current operating identity?

Which two businesses now sit inside the company?

This architecture is unusual for a company of Valion’s size. It combines a high-risk drug-development program with manufacturing infrastructure that could either become a strategic advantage or create a substantial fixed-cost burden. The company’s investor overview presents the thesis as three connected assets: Entolimod, domestic biomanufacturing and a government-development pathway.

Valion does not yet have a mature recurring-revenue model. Its continuing operations reported no revenue line in the quarter ended March 31, 2026, while the remaining ClearUP consumer-device sales were classified as discontinued operations and ended on February 28, 2026. The business model is therefore prospective: cash inflows must eventually come from government-supported development, government procurement, approved therapeutic sales, licensing or partnerships, and third-party CDMO contracts.

What are the four economic pathways?

Which revenue source matters most today?

The newest filed financial package is the Form 10-Q for the quarter ended March 31, 2026. It captures the first full quarter after the Velocity Bioworks acquisition and shows a sharp expansion in operating costs before meaningful continuing revenue emerged.

How did the cost base change?

What changed on the balance sheet?

Cash fell from $12.645 million at December 31, 2025 to $7.215 million at March 31, 2026. Total assets rose to $38.215 million because the company recognized inventory, lease right-of-use assets and the acquired manufacturing operation, but total liabilities also climbed to $19.667 million. The convertible note balance was $6.899 million, non-current lease liabilities were $9.643 million, and accumulated deficit reached $59.034 million. Common shares outstanding increased from 2,525,778 at year-end 2025 to 2,879,857 at quarter-end.

The most important history is compressed into roughly eighteen months. Earlier Tivic was a consumer health and bioelectronic-medicine company built around ClearUP and non-invasive nerve-stimulation programs. The 2025 strategy abandoned that operating model and acquired a late-stage biologics asset plus a manufacturing platform. The 2025 Form 10-K is therefore less a normal annual comparison than a record of a corporate reconstruction.

Which turning points still shape the business?

1. 2016
   Tivic was founded as a bioelectronic-medicine company, establishing the public-company shell, device-development capabilities and early financing history.
2. 2019
   ClearUP launched commercially. It demonstrated regulatory and commercialization execution but never created the scale needed to finance a broader pipeline.
3. 2021
   The company reincorporated in Delaware and completed its initial public offering, creating access to public equity markets that later funded the strategic pivot.
4. February 2025
   Tivic licensed worldwide rights to Entolimod for ARS and options for additional indications, acquiring more than fifteen years of development history rather than starting a new molecule from discovery.
5. December 2025
   The company acquired Scorpius manufacturing assets for approximately $16.3 million through Velocity Bioworks and simultaneously ended ClearUP sales and ncVNS development.
6. March–April 2026
   Michael K. Handley became CEO, and Tivic rebranded as Valion Bio, aligning leadership and corporate identity with the biopharma strategy.
7. July 2026
   Management reported ongoing government engagement, planned neutropenia studies and a 200-fold Entolimod manufacturing scale-up at 50-liter fermentation volume.

Entolimod is a recombinant protein designed to activate Toll-like Receptor 5, or TLR5, and downstream NF-κB signaling. The intended effect is broader than stimulating one blood-cell lineage: the company argues that the mechanism may support neutrophil, platelet and red-blood-cell recovery while also protecting gastrointestinal tissue. For ARS, human efficacy trials are unethical, so development relies on the FDA Animal Rule, under which well-controlled animal efficacy data can support approval when human efficacy studies cannot be performed.

How advanced is the pipeline?

What is the latest operating milestone?

The company’s July 14, 2026 business update stated that BARDA, NIAID, AFRRI and the U.S. Department of War discussions were continuing, while Ukraine’s Ministry of Health had requested information about possible strategic-reserve evaluation. Importantly, no funding, procurement, stockpiling or authorization agreement had been executed. That distinction separates a credible opportunity from booked economics.

Valion does not possess a conventional moat based on revenue scale, brand, network effects or switching costs. Its possible advantage is a bundled resource position: a mature development dossier, FDA designations, government relationships, licensed intellectual property and controlled domestic manufacturing. In resource-based strategy terms, the package may be valuable and difficult to recreate quickly, but it is not yet proven commercially.

Which resources could create defensibility?

Where is Valion positioned strategically?

Velocity Bioworks could shorten scheduling, support supply-chain security and create third-party revenue. It can also magnify losses if utilization remains low. The May 2026 exclusive commercial license for the BioScan-NMR platform illustrates the attempt to add differentiated analytics services, but commissioning and customer adoption must still be demonstrated.

Competition must be separated into two markets. Entolimod competes against approved medical countermeasures and oncology supportive-care agents, while Velocity Bioworks competes against established contract manufacturers. Buyer power is high in both: government agencies control procurement in biodefense, and biotechnology clients can compare CDMO quality, timelines, technical capability and price.

Which therapies define the benchmark?

How difficult is the CDMO market?

The CDMO opportunity is commercially nearer than an approved drug, but it is not automatically easier. Contracts are project-based and may be delayed, reduced or cancelled. Clients place high value on current good manufacturing practice compliance, validated equipment, quality documentation, technical staff and on-time delivery. Larger CDMOs possess deeper customer relationships, broader capacity and stronger balance sheets. Valion’s niche is intended to be early-stage biologics and Phase I or Phase II programs, where smaller clients may value attention and flexibility. The risk is that a single San Antonio campus concentrates regulatory, equipment, environmental and operational disruption in one location.

The balance sheet contains real assets and financing capacity, but financial strength is weak because cash burn is high, continuing revenue is minimal and the auditor and management identify substantial doubt about the company’s ability to continue as a going concern. At December 31, 2025, cash was $12.645 million after $18.347 million of financing cash inflows during the year. By March 31, 2026, $5.011 million of operating cash had been consumed in one quarter.

What does cash runway look like?

How is the company funding the gap?

Funding instruments include common stock, preferred stock, warrants, a senior secured convertible note and an equity line of credit. On June 17, 2026, Valion issued 250 Series B preferred shares at $1,000 each and a warrant for 156,026 common shares at an exercise price of $0.616280, raising $250,000. The official June financing filing shows why enterprise value cannot be assessed using common shares alone: preferred conversions, note conversions and warrants can materially expand the fully diluted share count.

Valion has one vote per common share and no founder-controlled dual-class structure. Preferred shares were non-voting on the 2026 annual-meeting proposals, but their conversion economics matter because they can become common equity. Governance influence is therefore split between a small board, management, common shareholders and financing counterparties whose contractual rights can shape future issuance.

Who owns and influences the stock?

The ownership figures come from the 2026 proxy statement and a subsequent Schedule 13G. Investors should distinguish voting ownership from contingent beneficial ownership created by preferred securities, warrants and conversion blockers.

What does the board’s capital-allocation policy reveal?

The board has prioritized talent retention, pipeline spending, manufacturing readiness and access to capital rather than dividends or repurchases. That is rational for a pre-revenue biotech, but the scale of the equity plan relative to the common share base makes dilution a core governance metric. Michael K. Handley became CEO in March 2026 after leading the biopharma unit, while Lisa Wolf serves as CFO. The board has four directors, and Statera retains a contractual right to nominate one qualified independent director, although it had not exercised that right by the proxy date.

A conventional DCF is unusually fragile for Valion because current revenue is not a useful base year. Analysts need a probability-weighted model that separates government-supported ARS economics, therapeutic indications, CDMO services and financing dilution. The most important variables are milestone timing, probability of approval, procurement volume, gross margin at manufacturing scale, facility utilization, clinical spending and the fully diluted capital structure.

Which KPIs matter most?